Found 18 matching trials
A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)
PHASE2The purpose of this study is to evaluate the anti-psoriatic effect of LP011...
Location
Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD)
Dermatopharmacokinetic Trial of LEO 90100 Foam
PHASE1This is a phase 1, single centre trial in Japanese healthy male subjects co...
Location
Investigational site
Vasoconstriction Trial With LEO 90100 Aerosol Foam
PHASE1Vasoconstriction study with LEO 90100...
LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris
PHASE3The purpose of this trial is to compare the efficacy of treatment with LEO ...
Location
Central Dermatology
Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris
PHASE3Comparison of the efficacy of LEO 90100 foam with Dovobet® ointment in the ...
Location
Leo Pharma Investigational Site
A Vasoconstriction Study With LEO 90100
PHASE1The purpose of this study is to compare the pharmacodynamic activity of LEO...
Location
CPCAD, Centre de Pharmacologie Clinique Appliquée à la Dermatologie
A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris
PHASE2The purpose of the study is to evaluate the anti-psoriatic effect of LEO 90...
Location
Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD)
LEO 90100 in the Treatment of Psoriasis Vulgaris
PHASE2The purpose of this study is to investigate whether LEO 90100, calcipotriol...
Location
Burke Pharmaceutical Research
A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris
PHASE2The purpose of this study is to evaluate the anti-psoriatic effect of LEO 9...
Location
Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD)
Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris
PHASE3To gather insight on how product attributes affect usability by investigati...
Location
K.Papp Clinical Research Inc.